QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
QQQ   309.88 (+2.07%)
AAPL   154.65 (+1.92%)
MSFT   267.56 (+4.20%)
META   191.62 (+2.99%)
GOOGL   107.64 (+4.61%)
AMZN   102.11 (-0.07%)
TSLA   196.81 (+1.05%)
NVDA   221.73 (+5.14%)
NIO   10.92 (-0.09%)
BABA   105.50 (+0.05%)
AMD   85.91 (+2.66%)
T   19.25 (-1.69%)
F   13.45 (+2.36%)
MU   62.13 (+3.58%)
CGC   2.82 (-4.41%)
GE   82.11 (-0.29%)
DIS   111.63 (+1.60%)
AMC   6.18 (-9.12%)
PFE   43.59 (-0.39%)
PYPL   83.23 (+1.09%)
NFLX   362.95 (+0.41%)
NASDAQ:ACRS

Aclaris Therapeutics - ACRS Stock Forecast, Price & News

$14.08
+0.35 (+2.55%)
(As of 02/7/2023 12:00 AM ET)
Add
Compare
Today's Range
$13.61
$14.16
50-Day Range
$13.73
$17.95
52-Week Range
$9.84
$18.96
Volume
931,857 shs
Average Volume
573,570 shs
Market Capitalization
$938.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.00

Aclaris Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
120.2% Upside
$31.00 Price Target
Short Interest
Healthy
5.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.13mentions of Aclaris Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$460,650 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.39) to ($1.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

306th out of 1,029 stocks

Pharmaceutical Preparations Industry

139th out of 504 stocks

ACRS stock logo

About Aclaris Therapeutics (NASDAQ:ACRS) Stock

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Stock News Headlines

ACRS Aclaris Therapeutics, Inc.
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Aclaris Therapeutics Provides 2023 Outlook
SVB Securities Keeps Their Buy Rating on Aclaris Therapeutics (ACRS)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Aclaris Therapeutics Announces Key Leadership Transitions
Aclaris Therapeutics Looks Promising on the Charts
See More Headlines
Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Company Calendar

Last Earnings
11/02/2021
Today
2/07/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRS
Employees
72
Year Founded
2012

Price Target and Rating

Average Stock Price Forecast
$31.00
High Stock Price Forecast
$38.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+120.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-90,860,000.00
Net Margins
-349.26%
Pretax Margin
-349.26%

Debt

Sales & Book Value

Annual Sales
$6.76 million
Book Value
$3.22 per share

Miscellaneous

Free Float
62,215,000
Market Cap
$938.85 million
Optionable
Optionable
Beta
0.57

Social Links


Key Executives

  • Douglas J. Manion
    President, Chief Executive Officer & Director
  • Kevin Balthaser
    Chief Financial Officer
  • Gail Cawkwell
    Chief Medical Officer
  • Joseph B. MonahanJoseph B. Monahan
    Chief Scientific Officer
  • Monica Salamea
    Vice President-Clinical Operations













ACRS Stock - Frequently Asked Questions

Should I buy or sell Aclaris Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACRS shares.
View ACRS analyst ratings
or view top-rated stocks.

What is Aclaris Therapeutics' stock price forecast for 2023?

6 Wall Street analysts have issued 12-month price objectives for Aclaris Therapeutics' shares. Their ACRS share price forecasts range from $25.00 to $38.00. On average, they predict the company's stock price to reach $31.00 in the next year. This suggests a possible upside of 120.2% from the stock's current price.
View analysts price targets for ACRS
or view top-rated stocks among Wall Street analysts.

How have ACRS shares performed in 2023?

Aclaris Therapeutics' stock was trading at $15.75 on January 1st, 2023. Since then, ACRS shares have decreased by 10.6% and is now trading at $14.08.
View the best growth stocks for 2023 here
.

Are investors shorting Aclaris Therapeutics?

Aclaris Therapeutics saw a drop in short interest in January. As of January 15th, there was short interest totaling 2,840,000 shares, a drop of 5.0% from the December 31st total of 2,990,000 shares. Based on an average daily volume of 349,100 shares, the short-interest ratio is currently 8.1 days. Currently, 5.5% of the company's stock are short sold.
View Aclaris Therapeutics' Short Interest
.

When is Aclaris Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our ACRS earnings forecast
.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) announced its earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.07. The biotechnology company had revenue of $1.66 million for the quarter, compared to the consensus estimate of $1.82 million. Aclaris Therapeutics had a negative net margin of 349.26% and a negative trailing twelve-month return on equity of 39.41%.

What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aclaris Therapeutics own?
What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Frazier Life Sciences Management L.P. (0.44%), Allspring Global Investments Holdings LLC (0.10%), Strs Ohio (0.05%), Fox Run Management L.L.C. (0.02%), Handelsbanken Fonder AB (0.02%) and ProShare Advisors LLC (0.02%). Insiders that own company stock include Andrew N Schiff, David N Gordon, Frank Ruffo, Joseph Monahan, Kamil Ali-Jackson and Neal Walker.
View institutional ownership trends
.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $14.08.

How much money does Aclaris Therapeutics make?

Aclaris Therapeutics (NASDAQ:ACRS) has a market capitalization of $938.85 million and generates $6.76 million in revenue each year. The biotechnology company earns $-90,860,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The official website for the company is www.aclaristx.com. The biotechnology company can be reached via phone at (484) 324-7933, via email at investors@aclaristx.com, or via fax at 484-320-2344.

This page (NASDAQ:ACRS) was last updated on 2/7/2023 by MarketBeat.com Staff